Objective To systematically assess credibility and certainty of associations between cannabis, cannabinoids, and cannabis based medicines and human health, from observational studies and randomised controlled trials (RCTs).
Design Umbrella review.
Data sources PubMed, PsychInfo, Embase, up to 9 February 2022.
Eligibility criteria for selecting studies Systematic reviews with meta-analyses of observational studies and RCTs that have reported on the efficacy and safety of cannabis, cannabinoids, or cannabis based medicines were included. Credibility was graded according to convincing, highly suggestive, suggestive, weak, or not significant (observational evidence), and by GRADE (Grading of Recommendations, Assessment, Development and Evaluations) (RCTs). Quality was assessed with AMSTAR 2 (A Measurement Tool to Assess Systematic Reviews 2). Sensitivity analyses were conducted.
Results 101 meta-analyses were included (observational=50, RCTs=51) (AMSTAR 2 high 33, moderate 31, low 32,
/PRNewswire/ The "Global Cancer Vaccine Partnering Terms and Agreements 2010-2023" report has been added to ResearchAndMarkets.com s offering. The Global.
Multiple System Atrophy (MSA) Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline as Leading 20+ Companies Working in the Domain | medgadget.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medgadget.com Daily Mail and Mail on Sunday newspapers.